Abstract
Background Upon treatment with biopharmaceuticals, the immune system may produce anti-drug antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis patients treated with interferon β (IFNβ) develop ADA, for which a genetic predisposition exists. Here, we present a genome-wide association study on ADA and predict the occurrence of antibodies in multiple sclerosis patients treated with different interferon β preparations.
Methods We analyzed a large sample of 2,757 genotyped and imputed patients from two cohorts, split between a discovery and a replication dataset. Binding ADA (bADA) levels were measured by capture-ELISA, neutralizing ADA (nADA) titers using a bioassay. Genome-wide association analyses were conducted stratified by cohort and treatment preparation, followed by fixed-effects meta-analysis.
Results Binding ADA levels and nADA titers were correlated and showed a significant heritability (47% and 50%, respectively). The risk factors differed strongly by treatment preparation: The top-associated and replicated variants for nADA presence were the HLA-associated variants rs77278603 in IFNβ-1a s.c.-(odds ratio (OR)=3.55 (95% confidence interval=2.81-4.48), p=2.1×10−26) and rs28366299 in IFNβ-1b s.c.-treated patients (OR=3.56 (2.69-4.72), p=6.6×10−19). The rs77278603-correlated HLA haplotype DR15-DQ6 conferred risk specifically for IFNβ-1a s.c. (OR=2.88 (2.29-3.61), p=7.4×10−20) while DR3-DQ2 was protective (OR=0.37 (0.27-0.52), p=3.7×10−09). The haplotype DR4-DQ3 was the major risk haplotype for IFNβ-1b s.c. (0R=7.35 (4.33-12.47), p=1.5×10−13). These haplotypes exhibit large population-specific frequency differences. In a cohort of IFNβ-1a s.c.-treated patients, prediction models for nADA reached an AUC of 0.91 (0.85-0.95), a sensitivity of 0.78, and a specificity of 0.90. Patients with the top 30% of genetic risk had, compared to patients in the bottom 30%, an OR of 73.9 (11.8-463.6, p=4.4×10−06) of developing nADA.
Conclusions We identified several HLA-associated genetic risk factors for ADA against interferon β, which were specific for treatment preparations and population backgrounds. Genetic prediction models could robustly identify patients at risk for developing ADA and might be used for personalized therapy recommendations and stratified ADA screening in clinical practice. These analyses serve as a roadmap for genetic characterizations of ADA against other biopharmaceutical compounds.
Competing Interest Statement
TFMA, JL, DM, MR, VG, LA, CG, PEHJ, IK and MP have no competing interests to declare. CH is an employee of Sanofi Genzyme. MA has received speaker honoraria and/or travel grants from Biogen, Novartis, Merck and Sanofi Genzyme. HH has participated in meetings sponsored by, received speaker honoraria, or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Siemens, Teva, and received honoraria for acting as consultant for Biogen and Teva. BK received a research grant and travel compensations from Novartis outside the submitted work. FS has served on scientific advisory boards, been on the steering committees of clinical trials, served as a consultant, received support for congress participation, received speaker honoraria, or received research support for his laboratory from Biogen, Merck, Novartis, Roche, Sanofi Genzyme and Teva. TO has received unrestricted MS research grants, and honoraria for advisory boards/lectures from Biogen, Novartis, Sanofi, Merck and Roche. SeS is a former employee and has stocks and/or stock options in Novartis. FD has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Almirall, Alexion, Biogen, Celgene, Genzyme-Sanofi, Merck, Novartis Pharma, Roche, and TEVA ratiopharm. His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders). AFH has received unrestricted research grants from Merck-Serono, BiogenIdec; served as consultant for Johnson & Johnson; and received honoraria for lectures by BiogenIdec and Sanofi-Aventis. BH has served on scientific advisory boards for Novartis; he has served as DMSC member for AllergyCare and TG therapeutics; he or his institution have received speaker honoraria from Desitin; holds part of a patent for the detection of antibodies against KIR4.1 in a subpopulation of patients with MS. None of these conflicts are relevant to the topic of the study. BMM and BH hold parts of a patent for genetic determinants of neutralizing antibodies to interferon.
Funding Statement
This study was supported by the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115303 (ABIRISK), resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and EFPIA companies’ in kind contribution. TFMA, CG, and BH were supported by the German Federal Ministry of Education and Research (BMBF) through the DIFUTURE consortium of the Medical Informatics Initiative Germany (grant 01ZZ1804A) and by the European Union’s Horizon 2020 Research and Innovation Programme (grant MultipleMS, EU RIA 733161). TFMA and BMM were supported by the BMBF through the Integrated Network IntegraMent, under the auspices of the e:Med Programme (grant 01ZX1614J). LA received funding from a clinician scientist program by the Munich Cluster for Systems Neurology (SyNergy). Christiane Gasperi received a research stipend from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation). TO has research funding from the Swedish Research Council, the Swedish Brain Foundation and Margaretha af Ugglas Foundation. This research was performed using a reference panel assembled by the Type 1 Diabetes Genetics Consortium (T1DGC), a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Child Health and Human Development (NICHD), and Juvenile Diabetes Research Foundation International (JDRF). The data were supplied by the NIDDK Central Repositories. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated and analyzed during the current study are available from the corresponding authors on reasonable request.
- List of abbreviations
- ADA
- anti-drug antibodies
- AF
- allele frequency
- AUC
- area under the receiver operating characteristic curve
- bp
- base pairs
- bADA
- binding ADA
- CI
- 95 % confidence interval
- eQTL
- expression quantitative trait locus
- GWAS
- genome-wide association study
- IFNβ
- Interferon β
- i.m.
- intramuscular
- HLA
- human leukocyte antigen
- kbp
- kilo base pairs
- KI
- Karolinska Institutet Stockholm Sweden
- LD
- linkage disequilibrium
- MAD
- median absolute deviation
- MHC
- major histocompatibility complex
- MAF
- minor allele frequency
- MDS
- multidimensional scaling
- MS
- multiple sclerosis
- nADA
- neutralizing ADA
- OR
- odds ratio
- s.c.
- subcutaneous
- PRS
- polygenic risk scores
- SD
- standard deviation
- SE
- standard error
- SNP
- single nucleotide polymorphism
- TUM
- Technical University of Munich, Germany
